To include your compound in the COVID-19 Resource Center, submit it here.

Afexa, Paladin deal

Paladin began an unsolicited tender offer to acquire the 85.1% of Afexa it does not already own for either C$0.55

Read the full 208 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE